This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cingolani, director of Cardiogenetics and Preclinical Research in the Department of Cardiology in the Smidt Heart Institute at Cedars-Sinai, is exploring new ways to help patients with ventricular tachycardia (VT), a recurring, abnormally fast and irregular heartbeat that starts in the lower chambers, or ventricles, of the heart.
The first randomized trial to investigate preventive ablation of a potential arrhythmogenic substrate associated with coronary chronic total occlusion (CTO) in patients at high risk of ventricular arrhythmias (VAs) reduces the risk of appropriate implantable cardioverter-defibrillator (ICD) therapy and unplanned hospitalization in patients with no (..)
Ventricular tachycardia is a potentially life threatening cardiac arrhythmia. On the ECG, ventricular tachycardia can be defined as three or more ventricular ectopic beats occurring in a sequence at a rate more than 100 per minute. Another rare form of ventricular tachycardia is bidirectional ventricular tachycardia.
Patients suffering recurrent Ventricular Tachycardia (VT) despite antiarrhythmic drugs, defibrillator and ablation remain at significant risk of morbidity and mortality. Although cardiac radioablation (RA) has demonstrated promise, results are heterogenous.
An 18-year-old male with arrhythmogenic cardiomyopathy was referred for catheter ablation of ventricular tachycardia after experiencing appropriate implantable cardioverter-defibrillator (ICD) shock. Six months prior, he had undergone uncomplicated implantation of an extravascular ICD (EV-ICD) [1].
Optimization of implantable cardioverter defibrillator (ICD) programming is essential to minimize inappropriate shocks, and to ensure appropriate ICD therapies are delivered for slower ventricular tachycardia (VT).
Over the past years, patients with tetralogy of Fallot (TOF) have experienced numerous improvements in different treatment modalities consisting of a mixture of surgical procedures, transcatheter interventions including ablation therapy, and implantable cardioverter-defibrillator implantation procedures.
Implantable cardioverter defibrillator (ICD) prevents sudden cardiac death (SCD) in patients with ischemic cardiomyopathy (ICM). Catheter ablation has been shown to effectively reduce ventricular tachycardia (VT) recurrence, yet its efficacy in patients without an ICD implantation remains uncertain.
Patients with repaired tetralogy of Fallot are at risk of ventricular tachycardia (VT) and sudden cardiac death. Historically, risk stratification electrophysiologic studies involved programmed ventricular stimulation with VT induction guiding implantable cardioverter-defibrillator (ICD) implantation or VT ablation.
Recent advancements in catheter ablation for structural ventricular tachycardia (VT), such as high-density mapping and cardiac imaging-based detection of target areas, have significantly improved the efficacy of ablation procedures.
In the PARTITA trial antitachycardia pacing (ATP) predicted the occurrence of implantable cardioverter-defibrillator (ICD) shocks. Catheter ablation of ventricular tachycardia after the first shock reduced the risk of death or worsening heart failure (wHF).
Treatment options, which consist primarily of antiarrhythmic medications, catheter ablation procedures, and autonomic modulation, are limited by mediocre effectiveness, invasiveness, and side effects including potential end-organ toxicities2-4.
Ablation will be performed with the use of a substrate-based approach in which the myocardial scar is mapped and ablated while the heart remains predominantly in sinus rhythm. Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx).
This progressed to electrical storm , with incessant PolyMorphic Ventricular Tachycardia ( PMVT ) and recurrent episodes of Ventricular Fibrillation ( VFib ). He required multiple defibrillations within a period of a few hours. An ICD ( Implantable Cardioverter Defibrilator ) was placed prior to discharge. What do you think?
Radiofrequency ablation has shown some potential in disrupting ventricular tachycardia circuits, with combined endo and epicardial ablation yielding better results which could be considered at the index procedure. Additionally, the impact of sotalol and amiodarone is inconsistent with studies reporting contradictory results.
During observation in the ED the patient had multiple self-terminating runs of Non-Sustained monomorphic Ventricular Tachycardia (NSVT). The patient has been scheduled for a PVC ablation procedure. This patient very likely has some form of idiopathic ventricular tachycardia. Potassium and magnesium serum levels were normal.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content